#BiotechHangout: Grace Colon, Chris Garabedian, Sam Fazeli, Paul Matteis, Yaron Werber, John Stanford on policy: NDAA provisions, industry trends: $1.85B in biotech financings, $XBI, $LLY’s acquisitive strategy, Fosun+$PFE, confs: #ASH25, #ESMOAsia, #SUO25, obesity data, Endpts 100: bit.ly/4q32CMO

Inside ESMO Asia 2025 with Angela Lamarca - OncoDaily Inside ESMO Asia 2025 with Angela Lamarca / Angela Lamarca, cancer, ESMO, ESMO Asia, ESMO Asia 2025, ESMO Asia 25, ESMOAsia25, Fabrice Andre, OncoDaily,

Inside ESMO Asia 2025 with Angela Lamarca

@myesmo.bsky.social

oncodaily.com/voices/esmo-...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMOAsia #ESMOAsia25 #ESMOAsia2025

Inside ESMO Asia 2025 with David Planchard - OncoDaily Inside ESMO Asia 2025 with David Planchard / cancer, David Planchard, ESMO, ESMO Asia 2025, ESMO Asia 25, ESMOAsia25, OncoDaily, Oncology

Inside ESMO Asia 2025 with David Planchard

@myesmo.bsky.social

oncodaily.com/voices/esmo-...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMOAsia #ESMOAsia25 #ESMOAsia2025

Inside ESMO Asia 2025 with Deborah Mukherji - OncoDaily Inside ESMO Asia 2025 with Deborah Mukherji / cancer, Deborah Mukherji, ESMO, ESMO Asia 2025, ESMOAsia2025, ESMOAsia25, OncoDaily, Oncology

Inside ESMO Asia 2025 with Deborah Mukherji

@dmukherji.bsky.social
@myesmo.bsky.social

oncodaily.com/voices/esmo-...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMOAsia #ESMOAsia25 #ESMOAsia2025

Episode 371: TROPICS-04 Results from ESMO Asia by The Uromigos Jonathan Rosenberg joins Brian and Tom to discuss this important phase 3 trial and efficacy and toxicity signals.

20/ @Uromigos thoroughly addressed of sacitizumab govitecan TROPiCS-04 findings presented at #ESMOAsia
🎧Worth a listen 👉 bit.ly/UromigosEp371
#OncSky

I had a great time at my first #ESMOAsia! Saw old friends, made new ones, and experienced the beautiful city of Singapore. Thank you to the organizers for a fantastic meeting and for the opportunity to share my thoughts on #Theranostics
#FirstBskyPost

The landscape of personalised medicine in the HR+ MBC space is constantly changing. Great summary at #ESMOAsia of how we incorporate biomarkers into our treatment sequencing.

Stayed active during 17-hour flight from SEA->Singapore :-) Looking forward to present TROPiCS04 phase 3 trial data at #ESMOASIA on Dec 7 ~10am local time discussed by Dr. Friedlander @oncoalert.bsky.social @achoud72.bsky.social @erplimackmd.bsky.social @valdesan.bsky.social @fredhutch.bsky.social

Kicking off #ESMOAsia with a great session on precision medicine.

So many potential benefits of oral over IV PD-L1 agents… most of all economic costs + patient QoL. Could this be the future?

Looking forward to this debate tomorrow here in National Cancer #Singapore with a ⭐️ star-studded line up! 🔥 Register below and see you tomorrow!

#CancerImmunotherapy
#ESMOAsia
#NCCS